• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    AbbVie Invites People Living with Migraine to Enter the Second Annual AbbVie Migraine Career Catalyst Award™ Contest to Support Their Professional Goals

    6/3/25 8:15:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABBV alert in real time by email
    • The AbbVie Migraine Career Catalyst Award™ contest is now open for entries, offering financial support to help winners pursue career and professional development goals.
    • As the only company with three approved products designed to meet patient needs across the spectrum of migraine, AbbVie is committed to supporting the migraine community beyond treatment.
    • Migraine affects productivity and career growth—up to 90% of people with migraine report it interferes with their ability to function at work, highlighting the need for meaningful support beyond treatment.

    NORTH CHICAGO, Ill., June 3, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced the second annual AbbVie Migraine Career Catalyst Award™ contest is now accepting entries. AbbVie is proud to continue this nationwide initiative supporting people living with migraine by awarding 20 entrants with $2,500 each that they may use to pursue their personal, professional, and educational goals.

    "Migraine can be an invisible barrier to success in the workplace where the condition is often misunderstood or stigmatized," said Carl Cincinnato, executive director, Migraine at Work, a nonprofit initiative under the World Health Education Foundation dedicated to improving workplace environments for individuals living with migraine. "Initiatives like the AbbVie Migraine Career Catalyst Award™ contest not only provide financial support but also serve as a powerful form of advocacy for people living with migraine."

    Migraine is the second leading cause of disability worldwide,1 with symptoms like severe headaches, nausea, and sensitivity to light often disrupting day-to-day activities,2 making it difficult to maintain consistent performance at work or school.3 Nearly 90% of migraine-related productivity loss occurs while individuals continue working through symptoms. In an AbbVie study, more than half of people with chronic migraine, a form of migraine characterized by headaches on 15 or more days per month, reported that the disease had negatively affected their career.4 These findings underscore the importance of how raising awareness about migraine in all forms can help reduce stigma and foster a greater understanding of how it affects colleagues in the workplace.

    "Migraine can create significant challenges in the workplace that can limit career opportunities and growth," said Jag Dosanjh, senior vice president, AbbVie, president, neuroscience and eye care. "As part of our ongoing commitment to those living with migraine, we're pleased to continue the AbbVie Migraine Career Catalyst Award™ contest for the second year in a row. We aim to go beyond treatment and provide meaningful support that empowers individuals to move forward with confidence."

    Last year, 20 winners from diverse professional backgrounds used the award to take actionable steps toward their goals—whether that meant creating a migraine-friendly home office, expanding their professional networks at conferences, or sharpening their skills through development opportunities.

    One winner, Melody B., shared how the support helped her thrive in her field: "Despite migraine, I found my passion in Human Resources. This award has allowed me to pursue training and certifications in both HR and project management. With these credentials, I hope to enhance the employee experience and create a better workplace for all."

    Individuals living with migraine are invited to visit www.migrainecareercatalyst.com to submit an essay (up to 3,000 characters), a video (up to three minutes), or an audio clip (up to three minutes) detailing their experience with migraine, career goals, and how this award might help them in their career. Individuals can also visit the site to learn how past recipients used their financial awards to foster growth, confidence, and awareness in the workplace.

    The submission period for the AbbVie Migraine Career Catalyst Award™ contest is now open and will close at 12:00 p.m. Eastern Time (ET) on September 2, 2025. The winners will be announced on or about November 14, 2025. Please see the full contest Official Rules at http://www.migrainecareercatalyst.com/.

    NO PURCHASE NECESSARY. Open only to legal residents of the fifty United States, D.C., and Puerto Rico, age 18 or older. Void where prohibited by law. Approximate retail value of each prize is $2,500. Entries must be received before 12:00 p.m. (noon) ET on 9/2/25. Eligibility requirements and restrictions apply. Prior winners of the Contest are not eligible to participate in this year's Contest or win a prize. Please see full Contest Rules at MigraineCareerCatalyst.com.

    Sponsor: AbbVie Inc.

    About AbbVie in Migraine

    AbbVie is the only company with three approved products for the treatment of migraine. However, our commitment to the community goes beyond medicine. Through our research and partnerships with the migraine community – including patients, HCPs, and other stakeholders – AbbVie has a deep understanding of the challenges that people living with migraine can face in the workplace. We are dedicated to redefining how the impact of migraine in professional settings is understood and addressed. This commitment drove the creation of the AbbVie Migraine Career Catalyst Award™ contest, aimed at empowering people living with migraine to pursue their professional objectives.

    About AbbVie

    AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.

    US-NEUM-250044

    Contact(s):

    U.S. Media:

    Jackie Escobar

    +1 (908) 424-9930

    [email protected]

    References

    1. World Health Organization. Migraine and other headache disorders. March 6, 2024. Accessed October 1, 2024. https://www.who.int/news-room/fact-sheets/detail/headache-disorders
    2. American Migraine Foundation. What is migraine? January 21, 2021. Accessed January 31, 2024. https://americanmigrainefoundation.org/resource-library/what-is-migraine/
    3. Begasse de Dhaem O, Sakai F. Migraine in the workplace. eNeurologicalSci. 2022;27:100408. doi: 10.1016/j.ensci.2022.100408
    4. American Headache Society. Research highlights impact of migraine on career advancement and financial stability. June 27, 2018. Accessed May 21, 2024. https://americanheadachesociety.org/research/library/research-highlights-impact-of-migraine-on-career-advancement-and-financial-stability

     

    AbbVie logo

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/abbvie-invites-people-living-with-migraine-to-enter-the-second-annual-abbvie-migraine-career-catalyst-award-contest-to-support-their-professional-goals-302471286.html

    SOURCE AbbVie

    Get the next $ABBV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ABBV

    DatePrice TargetRatingAnalyst
    5/14/2025$205.00Buy → Neutral
    Citigroup
    4/22/2025$210.00Overweight
    Cantor Fitzgerald
    12/10/2024$191.00Neutral
    BofA Securities
    12/5/2024$180.00Outperform → Neutral
    Daiwa Securities
    11/22/2024$206.00Market Perform → Outperform
    Leerink Partners
    11/15/2024$205.00Outperform
    Wolfe Research
    11/4/2024Hold → Buy
    Argus
    10/17/2024$203.00Mkt Perform
    Bernstein
    More analyst ratings

    $ABBV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Falk Thomas J was granted 1,203 shares (SEC Form 4)

      4 - AbbVie Inc. (0001551152) (Issuer)

      5/13/25 5:05:30 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Freyman Thomas C was granted 1,203 shares, increasing direct ownership by 0.96% to 126,751 units (SEC Form 4)

      4 - AbbVie Inc. (0001551152) (Issuer)

      5/13/25 5:05:26 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Tilton Glenn F was granted 1,203 shares, increasing direct ownership by 2% to 51,564 units (SEC Form 4)

      4 - AbbVie Inc. (0001551152) (Issuer)

      5/13/25 5:05:28 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABBV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AbbVie Invites People Living with Migraine to Enter the Second Annual AbbVie Migraine Career Catalyst Award™ Contest to Support Their Professional Goals

      The AbbVie Migraine Career Catalyst Award™ contest is now open for entries, offering financial support to help winners pursue career and professional development goals. As the only company with three approved products designed to meet patient needs across the spectrum of migraine, AbbVie is committed to supporting the migraine community beyond treatment.Migraine affects productivity and career growth—up to 90% of people with migraine report it interferes with their ability to function at work, highlighting the need for meaningful support beyond treatment.NORTH CHICAGO, Ill., June 3, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced the second annual AbbVie Migraine Career Catalyst Awar

      6/3/25 8:15:00 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AbbVie to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

      NORTH CHICAGO, Ill., June 3, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) will participate in the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025. Management will participate in a fireside chat at 10:20 a.m. Central time. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several ke

      6/3/25 8:00:00 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AbbVie Features New Data Across Difficult-to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio

      -    Key oral presentations highlight new data from AbbVie's novel investigational antibody-drug conjugates (ADCs) including telisotuzumab adizutecan (ABBV-400, Temab-A) in advanced non-small cell lung cancer (NSCLC), ABBV-706 in high-grade neuroendocrine neoplasms (NENs) and pivekimab sunirine (PVEK) in blastic plasmacytoid dendritic cell neoplasm (BPDCN). NORTH CHICAGO, Ill., May 27, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that key data from its broad oncology portfolio will be showcased across multiple oral presentations and posters at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting (May 30 - June 3, 2025). These new data highlight significant prog

      5/27/25 9:00:00 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABBV
    Financials

    Live finance-specific insights

    See more
    • AbbVie Reports First-Quarter 2025 Financial Results

      Reports First-Quarter Diluted EPS of $0.72 on a GAAP Basis, a Decrease of 6.5 Percent; Adjusted Diluted EPS of $2.46, an Increase of 6.5 Percent; These Results Include an Unfavorable Impact of $0.13 Per Share Related to Acquired IPR&D and Milestones Expense  Delivers First-Quarter Net Revenues of $13.343 Billion, an Increase of 8.4 Percent on a Reported Basis or 9.8 Percent on an Operational Basis  First-Quarter Global Net Revenues from the Immunology Portfolio Were $6.264 Billion, an Increase of 16.6 Percent on a Reported Basis, or 18.1 Percent on an Operational Basis; Global Skyrizi Net Revenues Were $3.425 Billion; Global Rinvoq Net Revenues Were $1.718 Billion; Global Humira Net Revenues

      4/25/25 7:43:00 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AbbVie to Host First-Quarter 2025 Earnings Conference Call

      NORTH CHICAGO, Ill., March 31, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) will announce its first-quarter 2025 financial results on Friday, April 25, 2025, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas in

      3/31/25 8:00:00 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity

      Partnership marks AbbVie's entrance into the obesity fieldAgreement will enable the incorporation of GUB014295, an amylin peptide discovered and developed by Gubra, into AbbVie's global infrastructure for developing and commercializing therapies for patients in needNORTH CHICAGO, Ill. and HØRSHOLM, Denmark, March 3, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) and Gubra A/S (CPSE:GUBRA), a company specializing in preclinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases, today announced a license agreement to develop GUB014295, a potential best-in-class, long-acting amylin analog for the treatment of obesity. "At AbbVie, we are focused on trans

      3/3/25 1:11:00 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABBV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $ABBV
    Leadership Updates

    Live Leadership Updates

    See more
    • AbbVie downgraded by Citigroup with a new price target

      Citigroup downgraded AbbVie from Buy to Neutral and set a new price target of $205.00

      5/14/25 8:54:15 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on AbbVie with a new price target

      Cantor Fitzgerald initiated coverage of AbbVie with a rating of Overweight and set a new price target of $210.00

      4/22/25 7:59:33 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BofA Securities resumed coverage on AbbVie with a new price target

      BofA Securities resumed coverage of AbbVie with a rating of Neutral and set a new price target of $191.00

      12/10/24 8:12:28 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors

      Richard A. Gonzalez to retire from the board of directors effective July 1, 2025NORTH CHICAGO, Ill., Feb. 14, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that its board of directors has unanimously elected chief executive officer (CEO) Robert A. Michael to assume the additional position of chairman, effective July 1, 2025. He will succeed Richard A. Gonzalez, who formerly served as AbbVie's CEO and has been chairman since the Company's formation in 2013. "I want to extend my heartfelt gratitude to Rick for his remarkable leadership and dedicated service," said Roxanne S. Austin, lead independent director. "The board and I have complete confidence in Rob, and we are fortunate to

      2/14/25 7:40:00 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer

      Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. T

      11/5/24 7:05:00 AM ET
      $ABBV
      $CCCC
      $IMGN
      $NVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Seaport Therapeutics Names Lauren White as Chief Financial Officer

      Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations Seaport Therapeutics ("Seaport or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. "I am so pleased to welcome Lauren as our CFO as we progress our clinical-stage pipeline of therapeutics for the treatme

      11/5/24 7:00:00 AM ET
      $ABBV
      $CCCC
      $IMGN
      $NVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $ABBV
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for VYALEV issued to ABBVIE INC

      Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

      10/18/24 4:38:13 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for VYALEV issued to ABBVIE INC

      Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form

      10/17/24 1:29:31 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for SKYRIZI issued to ABBVIE INC

      Submission status for ABBVIE INC's drug SKYRIZI (SUPPL-7) with active ingredient RISANKIZUMAB-RZAA has changed to 'Approval' on 06/18/2024. Application Category: BLA, Application Number: 761262, Application Classification:

      6/21/24 4:38:17 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABBV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by AbbVie Inc. (Amendment)

      SC 13G/A - AbbVie Inc. (0001551152) (Subject)

      2/13/24 4:55:55 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by AbbVie Inc. (Amendment)

      SC 13G/A - AbbVie Inc. (0001551152) (Subject)

      1/25/24 4:59:27 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by AbbVie Inc. (Amendment)

      SC 13G/A - AbbVie Inc. (0001551152) (Subject)

      2/9/23 10:54:46 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABBV
    SEC Filings

    See more
    • SEC Form SD filed by AbbVie Inc.

      SD - AbbVie Inc. (0001551152) (Filer)

      5/30/25 4:05:32 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by AbbVie Inc.

      10-Q - AbbVie Inc. (0001551152) (Filer)

      5/9/25 1:24:59 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - AbbVie Inc. (0001551152) (Filer)

      4/25/25 7:48:22 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care